(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases...
Stats | |
---|---|
Šios dienos apimtis | 6 585.00 |
Vidutinė apimtis | 2 534.00 |
Rinkos kapitalizacija | 88.44B |
EPS | €0 ( 2024-04-25 ) |
Kita pelno data | ( €0 ) 2024-07-26 |
Last Dividend | €0.570 ( 2023-07-06 ) |
Next Dividend | €0 ( N/A ) |
P/E | 12.10 |
ATR14 | €0.0880 (0.21%) |
Tūris Koreliacija
Bristol-Myers Squibb Co Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bristol-Myers Squibb Co Koreliacija - Valiuta/Žaliavos
Bristol-Myers Squibb Co Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €45.01B |
Bruto pelnas: | €34.31B (76.24 %) |
EPS: | €3.88 |
FY | 2023 |
Pajamos: | €45.01B |
Bruto pelnas: | €34.31B (76.24 %) |
EPS: | €3.88 |
FY | 2022 |
Pajamos: | €46.16B |
Bruto pelnas: | €36.02B (78.04 %) |
EPS: | €2.97 |
FY | 2021 |
Pajamos: | €46.39B |
Bruto pelnas: | €36.45B (78.57 %) |
EPS: | €3.15 |
Financial Reports:
No articles found.
Bristol-Myers Squibb Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0.540 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.215 | 1999-06-30 |
Last Dividend | €0.570 | 2023-07-06 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 97 | -- |
Total Paid Out | €33.94 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.93 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.68 | |
Div. Directional Score | 8.19 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
YCP.DE | Ex Dividend King | 2023-09-27 | Bi-Monthly | 0 | 0.00% | |
G24.DE | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
PND.F | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
BAC.DE | Ex Dividend Knight | 2023-10-09 | Quarterly | 0 | 0.00% | |
HXCK.DE | Ex Dividend Junior | 2023-05-11 | Sporadic | 0 | 0.00% | |
SIX2.DE | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
CMC.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
KTF.DE | Ex Dividend Knight | 2023-06-29 | Quarterly | 0 | 0.00% | |
UN9.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
EBA.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.178 | 1.500 | 6.43 | 9.65 | [0 - 0.5] |
returnOnAssetsTTM | 0.0843 | 1.200 | 7.19 | 8.63 | [0 - 0.3] |
returnOnEquityTTM | 0.263 | 1.500 | 8.19 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.591 | -1.000 | 4.09 | -4.09 | [0 - 1] |
currentRatioTTM | 1.427 | 0.800 | 7.86 | 6.29 | [1 - 3] |
quickRatioTTM | 1.237 | 0.800 | 7.43 | 5.94 | [0.8 - 2.5] |
cashRatioTTM | 0.515 | 1.500 | 8.25 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.436 | -1.500 | 2.74 | -4.11 | [0 - 0.6] |
interestCoverageTTM | 8.08 | 1.000 | 8.12 | 8.12 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.82 | 2.00 | 7.73 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.23 | 2.00 | 6.89 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.409 | -1.500 | 4.36 | -6.55 | [0 - 2.5] |
grossProfitMarginTTM | 0.762 | 1.000 | 0.627 | 0.627 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.209 | 1.000 | 7.82 | 7.82 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.334 | 1.000 | 9.25 | 9.25 | [0.2 - 2] |
assetTurnoverTTM | 0.473 | 0.800 | -0.180 | -0.144 | [0.5 - 2] |
Total Score | 10.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.47 | 1.000 | 8.94 | 0 | [1 - 100] |
returnOnEquityTTM | 0.263 | 2.50 | 8.84 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.23 | 2.00 | 7.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.258 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.82 | 2.00 | 7.73 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.591 | 1.500 | 4.09 | -4.09 | [0 - 1] |
pegRatioTTM | 0.194 | 1.500 | -2.04 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.308 | 1.000 | 4.80 | 0 | [0.1 - 0.5] |
Total Score | 5.68 |
Bristol-Myers Squibb Co
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.